^
Association details:
| Biomarker: | FDFT1 rearrangement + FGFR2 rearrangement |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma
Published date:
04/20/2022
Excerpt:
In this study, we report a case of advanced cholangiocarcinoma, in which the patient was unable to tolerate the adverse effects of standard first-line chemotherapy. Genetic testing suggested the presence of a novel variant resulting from FDFT1/FGFR2 rearrangement....the patient was prescribed anlotinib. After treatment, the tumor size continued to shrink, and no significant adverse effects were reported.
DOI:
https://doi.org/10.1016/j.ctarc.2022.100568
